Edition:
United Kingdom

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

244.10CHF
15 Dec 2017
Change (% chg)

CHF2.40 (+0.99%)
Prev Close
CHF241.70
Open
CHF242.90
Day's High
CHF244.80
Day's Low
CHF241.90
Volume
6,116,717
Avg. Vol
1,588,438
52-wk High
CHF273.00
52-wk Low
CHF226.10

Select another date:

Fri, Dec 15 2017

European Commission drops infringement action against Roche

Dec 15 The European Commission has closed an infringement procedure taken against Swiss pharma company Roche Holding AG without imposing any penalty, the European medicines regulator said on Friday.

BRIEF-Ionis Pharma Says Roche Has Exercised Option To License IONIS-HTT(Rx)

* IONIS PHARMACEUTICALS LICENSES IONIS-HTT RX TO PARTNER FOLLOWING SUCCESSFUL PHASE 1/2A STUDY IN PATIENTS WITH HUNTINGTON'S DISEASE

Roche: Tecentriq cocktail slows kidney cancer progression

ZURICH Combining Roche's Tecentriq immunotherapy with its older drug Avastin for the initial treatment of advanced kidney cancer reduced the risk of the disease worsening or of death in certain patients, the Swiss drugmaker said on Monday.

UPDATE 2-Roche: Tecentriq cocktail slows kidney cancer progression

* Swiss drugmaker aims to expand drug's indications (Adds analyst comment, shares)

Roche: Tecentriq cocktail slows kidney cancer progression

ZURICH Combining Roche's Tecentriq immunotherapy with its older drug Avastin reduced the risk of disease worsening or death (PFS) for the initial treatment of advanced kidney cancer in some patients, the Swiss drugmaker said on Monday

Roche: Tecentriq cocktail slows kidney cancer progression

ZURICH, Dec 11 Swiss drugmaker Roche said on Monday that a combination of its Tecentriq immunotherapy with its older drug Avastin reduced the risk of disease worsening or death (PFS) for the initial treatment of advanced kidney cancer in some patients.

Roche lymphoma drug drives high remission rate, longer survival: study

An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly longer than the standard treatment alone, according to data from a mid-stage trial released at a medical meeting on Sunday.

Roche lymphoma drug drives high remission rate, longer survival-study

Dec 10 An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly longer than the standard treatment alone, according to data from a mid-stage trial released at a medical meeting on Sunday.

Roche chairman confident new drugs will offset patent losses: report

ZURICH Roche Chairman Christoph Franz remains confident the Swiss drugmaker can offset revenue declines from patent expired medicines with new drugs, according to an interview published on Sunday in the Swiss newspaper NZZ am Sonntag.

Roche chairman confident new drugs will offset patent losses -- report

ZURICH, Dec 10 Roche Chairman Christoph Franz remains confident the Swiss drugmaker can offset revenue declines from patent expired medicines with new drugs, according to an interview published on Sunday in the Swiss newspaper NZZ am Sonntag.

Select another date: